Brad S Kahl, MD
Burger JA et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015;373(25):2425-37. Abstract
Davids MS. Targeting BCL-2 in B-cell lymphomas. Blood 2017;130(9):1081-8. Abstract
Fischer K et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med 2019;380(23):2225-36. Abstract
Moreno C et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): A multicenter, randomized, open-label, phase 3 trial. Lancet Oncol 2019;20(1):43-56. Abstract
Roberts AW et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 2016;374(4):311-22. Abstract
Shanafelt TD et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med 2019;381(5):432-43. Abstract
Shanafelt TD. Treatment of older patients with chronic lymphocytic leukemia: Key questions and current answers. Hematology Am Soc Hematol Educ Program 2013;2013(1):158-67. Abstract
Woyach JA et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 2018;379(26):2517-28. Abstract
Prof John G Gribben, MD, DSc, FMedSci
Flinn IW et al. The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood 2018;132(23):2446-55. Abstract
Ghia P et al. ASCEND phase 3 study of acalabrutinib vs investigator’s choice of rituximab plus idelalisib (IDR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). EHA 2019;Abstract LB2606.
Hillmen P et al. Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: The CLARITY study. J Clin Oncol 2019;37(30):2722-9. Abstract
Kater AP et al. Safety analysis of venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL): Second interim analysis from the phase II vision HO141 trial. EHA 2019;Abstract S108.
Seymour JF et al. Four-year analysis of MURANO study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Proc ASH 2019;Abstract 355.
Seymour JF et al. MURANO trial establishes feasibility of time-limited venetoclax-rituximab (VenR) combination therapy in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Proc ASH 2018;Abstract 184.
Seymour JF et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2018;378(12):1107-20. Abstract
Bruce D Cheson, MD
Brice P et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 1997;15(3):1110-7. Abstract
Cheson BD et al. Optimal management of adverse events from copanlisib in the treatment of patients with non-Hodgkin lymphomas. Clin Lymphoma Myeloma Leuk 2019;19(3):135-41. Abstract
Cheson BD et al. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol 2018;36(22):2259-66. Abstract
Crawford J et al. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol 2010;21(Suppl 5):248-51. Abstract
Fowler NH et al. RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R2) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma. ASCO 2018;Abstract 7500.
Leonard JP et al. AUGMENT: A phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol 2019;37(14):1188-99. Abstract
Marcus R et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 2017;377(14):1331-44. Abstract
Morschhauser F et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med 2018;379(10):934. Abstract
Salles G et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 2011;377(9759):42-51. Abstract
Sehn LH et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): A randomised, controlled, open-label, multicenter, phase 3 trial. Lancet Oncol 2016;17(8):1081-93. Abstract
Sehn LH et al. GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma. ASCO 2015;Abstract LBA8502.
Smith TJ et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical practice guideline update. J Clin Oncol 2015;33(28):3199-212. Abstract
Jeremy Abramson, MD
Davids MS et al. Revised dose ramp-up to mitigate the risk of tumor lysis syndrome when initiating venetoclax in patients with mantle cell lymphoma. J Clin Oncol 2018;[Epub ahead of print]. Abstract
Davids MS et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol 2017;35(8):826-33. Abstract
Dreyling M et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: An international, randomized, open-label, phase 3 study. Lancet 2016;387(10020):770-8. Abstract
Eyre T et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma post BTK inhibition therapy. EHA 2018;Abstract S855.
Gine E et al. Efficacy and safety of ibrutinib in combination with rituximab as frontline treatment for indolent clinical forms of mantle cell lymphoma (MCL): Preliminary results of GELTAMO IMCL-2015 phase II trial. Proc ASH 2019;Abstract 752.
Jain P, Wang M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol 2019;94(6):710-25. Abstract
Song Y et al. Zanubrutinib in patients with relapsed/refractory mantle cell lymphoma. Proc ICML 2019;Abstract 015.
Tam CS et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med 2018;378(13):1211-23. Abstract
Wang M et al. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia 2019;33(11):2762-6. Abstract
Wang M et al. Safety and preliminary efficacy in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) receiving lisocabtagene maraleucel (liso-cel) in TRANSCEND NHL 001. ASCO 2019;Abstract 7516.
Wang M et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): A single-arm, multicentre, phase 2 trial. Lancet 2018;391(10121):659-67. Abstract
Wang ML et al. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL): Results of the phase 2 ZUMA-2 study. Proc ASH 2019;Abstract 754.
Wang ML et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369(6):507-16. Abstract
Laurie H Sehn, MD, MPH
Cheson BD et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol 2014;32(27):3059-68. Abstract
Crump M et al. Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma. J Clin Oncol 2016;34(21):2484-92. Abstract
Davies A et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): An open-label, randomised, phase 3 trial. Lancet Oncol 2019;20(5):649-62. Abstract
Johnson P et al. Clinical impact of ibrutinib with R-CHOP in untreated non-GCB DLBCL co-expressing BCL2 and MYC genes in the phase 3 PHOENIX trial. Proc ASH 2019;Abstract 354.
Leonard JP et al. Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol 2017;35(31):3538-46. Abstract
Neelapu SS et al. Outcomes of patients (pts) ≥ 65 years of age in ZUMA-1, a pivotal phase 1/2 study of axicabtagene ciloleucel (Axi-cel) in refractory large B cell lymphoma (LBCL). ASCO 2019;Abstract 7555.
Nowakowski GS et al. Addition of lenalidomide to R-CHOP (R2CHOP) improves outcomes in newly diagnosed diffuse large B-cell lymphoma (DLBCL): First report of ECOG-ACRIN1412: A randomised phase 2 US Intergroup study of R2CHOP vs R-CHOP. Proc ICML 2019;Abstract 006.
Salles G. New drugs for old targets. Proc ICML 2019;Abstract EB17.
Schuster SJ et al. Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. Proc ASH 2019;Abstract 6.
Sehn LH et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38(2):155-65. Abstract
Sehn LH et al. Prognostic impact of BCL2 and MYC expression and translocation in untreated DLBCS: Results from the phase III GOYA study. Proc ICML 2019;Abstract 122.
Sun LL et al. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci Transl Med 2015;7(287):287ra70. Abstract
Thieblemont C et al. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2017;35(22):2473-81. Abstract
Tilly H et al. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: An open-label, non-randomised, phase 1b-2 study. Lancet Oncol 2019;20(7):998-1010. Abstract
Vitolo U et al. ROBUST: First report of phase III randomized study of lenalidomide/R-CHOP (R2-CHOP) in previously untreated ABC-type diffuse large B-cell lymphoma. Proc ICML 2019;Abstract 005.
Vitolo U et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol 2017;35(31):3529-37. Abstract
Witzig TE et al. Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: Final results from the PILLAR-2 randomized phase III trial. Ann Oncol 2018;29(3):707-14. Abstract
Younes A et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol 2019;37(15):1285-95. Abstract
Loretta Nastoupil, MD
Abramson JS et al. Pivotal safety and efficacy results from TRANSCEND NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas. Proc ASH 2019;Abstract 241.
Abramson JS et al. Updated safety and long-term clinical outcomes in TRANSCEND NHL 001, a pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. ASCO 2018;Abstract 7505.
Maus MV, June CH. Making better chimeric antigen receptors for adoptive T-cell therapy. Clin Cancer Res 2016;22(8):1875-84. Abstract
Nastoupil LJ et al. Axicabtagene ciloleucel (axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory large B-cell lymphoma: Real World Experience. Proc ASH 2018;Abstract 627.
Neelapu SS et al. 2-year follow-up and high-risk subset analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in patients with refractory large B cell lymphoma. Proc ASH 2018;Abstract 2967.
Neelapu SS et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017;377(26):2531-44. Abstract
Schuster SJ et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019;380(1):45-56. Abstract
van der Stegen SJ et al. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov 2015;14(7):499-509. Abstract